Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
6
Active, not recruiting, industry sponsors, Psychiatry, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed532
6 trials
Showing 1 to 6, recently updated first.
- Clinical Trial on Agitation in Alzheimer's DementiaPivotal-lookingActive, not recruiting
IGC Pharma, LLCIndustry
NCT05543681 · 164 participants (planned) · Start Oct 11, 2022 · Primary completion Nov 2026
Drug: IGC-AD1-Active; IGC-AD1-Placebo · For: Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden and 2 more
Sites: Maitland, Florida; Melbourne, Florida; Miami, Florida · 28 sites in all
- Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in AdultsActive, not recruiting
Autobahn Therapeutics, Inc.Industry
NCT06869187 · 35 participants (planned) · Start Mar 28, 2025 · Primary completion Apr 22, 2026
Drug: ABX-002 · For: Bipolar Disorder Depression
Sites: Walnut Creek, California; Cromwell, Connecticut; Hartford, Connecticut · 14 sites in all
- Study of SPG302 in Adults With SchizophreniaActive, not recruiting
SpinogenixIndustry
NCT06442462 · 32 participants (planned) · Start Aug 1, 2024 · Primary completion Mar 2026
Drug: SPG302; Placebo · For: Schizophrenia
Sites: Garden Grove, California; Box Hill, Australia; Melbourne, Australia
- A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderPivotal-lookingActive, not recruiting
COMPASS PathwaysIndustry
NCT05733546 · 102 participants · Start Jan 30, 2023 · Primary completion Sep 2025
Drug: Psilocybin · For: Major Depressive Disorder
Sites: La Jolla, California; Jacksonville, Florida; Rockville, Maryland · 5 sites in all
- A Study of ANAVEX3-71 in Adults With SchizophreniaActive, not recruiting
Anavex Life Sciences Corp.Industry
NCT06245213 · 71 participants · Start Mar 15, 2024 · Primary completion Jun 30, 2025
Drug: ANAVEX3-71 oral capsules; Placebo oral capsules · For: Schizophrenia
Sites: Marlton, New Jersey
- ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With DepressionActive, not recruiting
Eleusis TherapeuticsIndustry
NCT05434156 · 84 participants (planned) · Start Oct 27, 2022 · Primary completion Dec 2025
Drug: ELE-101; ELE-101 Placebo · For: Healthy Volunteers; Major Depressive Disorder; Depression
Sites: Liverpool, United Kingdom; Manchester, United Kingdom
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.